Case 1: Dr. Joannie Ivory presented on a refractory TNBC case highlighted limited treatment options after pembrolizumab. Panelists discussed ADC selection, T-DXd for HER2-low disease, and clinical trial enrollment for resistant disease.

Case 2: Dr. Teja Poosarla presented a case of inflammatory breast cancer reinforced standard treatment despite complete clinical response. Panelists recommended axillary dissection and radiation, emphasizing high recurrence risk and ongoing adjuvant therapy.

Case 3: Dr. Milana Dolezal presented a case of metastatic HR-positive, HER2-negative breast cancer with ESR1 and PI3K mutations highlighted individualized, oral treatment selection, balancing efficacy, comorbidities, and quality of life.

Case 4: Dr. Arya Roy presented a case of high-risk premenopausal HR+/HER2+ breast cancer supported neoadjuvant chemotherapy, multimodal adjuvant therapy, genomic testing, fertility counseling, and consideration of clinical trials.